| Date | Title | Description |
| 24.02.2026 | QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS | CAMBRIDGE, Mass., February 24, 2026 – QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegener... |
| 19.11.2024 | QurAlis’ ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed | CAMBRIDGE, Mass., November 19, 2024 – QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral scle... |
| 16.09.2024 | Pioneering New Frontiers in ALS and Cancer Treatment: The Role of QRL-101 and mIDH1 Inhibitors | In the realm of medical science, innovation is the lifeblood that fuels progress. Two recent developments stand out: QurAlis Corporation's QRL-101 for ALS and Vazyme's contributions to mIDH1 cancer treatment. Both represent significant stri... |
| 10.09.2024 | QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS | QRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients
Completed Phase 1 single-ascending dose (SAD) clinical trial of QRL-101 enrolled 88 participants; no report... |
| 10.09.2024 | QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS | CAMBRIDGE, Mass., September 10, 2024 – QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic... |
| 12.06.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals
Former Karuna CFO Brown brings more than... |
| 03.06.2024 | QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD | QRL-204 is a splice-switching ASO generated through QurAlis’ FlexASO™ Platform; represents Lilly’s first program targeting UNC13A in ALS and FTD
Parties to also collaborate to leverage QurAlis’ ALS and ASO development expertise to advance Q... |
| 04.03.2024 | QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia | UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical RNA alteration occurring in up to 63 percent of all ALS patients and up to one-third of all FTD cases
Preclinical data to be featured in a ... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry.
While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 06.04.2023 | QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS | First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients |
| 04.04.2023 | Latest Updates of 6 Viva's Portfolio Companies | HONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 10.03.2023 | QurAlis Closes $88 Million Series B |
CAMBRIDGE, MA, QurAlis Corporation, a clinical-stage biotechnology company, has closed an oversubscribed $88 million Series B financing, led by EQT Life Sciences.
>> Click here for more funding data on QurAlis
>> To export Q... |
| 09.03.2023 | QurAlis Closes $88M Series B Financing | QurAlis, a Cambridge, MA-based clinical-stage biotechnology company, raised $88M in Series B funding.
The round, which brought the total funds raised to $143.5M, was led by EQT Life Sciences, Sanofi Ventures, and Droia Ventures, with partic... |
| 09.03.2023 | ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies | QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ ALS therapy. |
| 09.03.2023 | QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases | EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round |
| 09.03.2023 | QurAlis Closes $88 Million Series B to Advance Precision Medicines for Neurodegenerative Diseases | - |
| 05.01.2023 | QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS | QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration |
| 27.07.2022 | Portfolio Highlights: Clinical and Financing Updates of AIxplorerBIO, Genhouse, VivaVision, Domain, Amberstone, Anji and QurAlis | SHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, its p... |
| 21.06.2022 | QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board | Industry veteran brings proven track record in building successful businesses and leading high-performance teams across large pharmaceutical, biotech, and specialty pharma companies |
| 26.05.2022 | Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron | SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio... |
| 29.01.2022 | ZK International : Announces Record Revenues of $99.41 Million, an Increase of 14.5% for the Fiscal Year 2021 - Form 6-K | ZK International Group Co., Ltd. Announces Record Revenues of $99.41 Million, an Increase of 14.5% for the Fiscal Year 2021
WENZHOU, China, Jan. 28, 2022 /PRNewswire/ -- ZK International Group Co., Ltd. (ZKIN) ("ZK International" ... |
| 14.09.2021 | QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2 | QRL-201 is a first-in-class molecule that rescues STATHMIN-2 loss of function in motor neuron disease models in the presence of TDP43 pathology |
| 14.09.2021 | QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2 | |
| 01.07.2020 | QurAlis Announces Agreement to Strengthen ALS Pipeline | Cambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced an agreement to in-license pre-clinical c... |
| 17.05.2020 | QurAlis raises $42M in Series A round to develop therapies for ALS | Carbon Health
Headquarters: San Francisco
Funding type: Series B1
Amount: $28 million
Carbon Health, which aims to deliver what it calls a seamless experience from virtual care to in-person care by combining technology with modern clinics, ... |
| 13.05.2020 | QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) | Funding led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery Fund |
| 13.05.2020 | QurAlis Raises $42M in Series A Financing | QurAlis Corporation, a Cambridge, Mass.-based biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, raised $42m in Series A financing.
The round, which brought to... |
| 13.05.2020 | QurAlis Raises $42M Series A Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a $42 million Series ... |
| 13.05.2020 | QurAlis Collects $42M in Series A |
CAMBRIDGE, MA, QurAlis Corporation announced the raise of a $42 million Series A financing.
>> Click here for more funding data on QurAlis
>> To export QurAlis funding data to PDF and Excel, click here
QurAlis Corporation... |
| 20.11.2018 | Term Sheet — Tuesday, November 20 | A CRYPTO COLLAPSE
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
The SEC took action against two cryptocurrency startups that staged ICOs. The companies, Airfox and Paragon Coin, agreed to p... |
| 20.11.2018 | Cambridge-Based QurAlis Raises $5.5 Million To Develop Therapeutics For Neurological Diseases | Cambridge, Massachusetts-based biotech company QurAlis announced that it has raised $5.5 million to develop therapeutics for neurological diseases. |
| 19.11.2018 | QurAlis Raises $5.5M in Seed Funding | QurAlis Corporation, a Cambridge, MA-based biotech company focused on developing precision therapeutics for ALS and other neurological diseases, is raising a seed extension, bringing the total funding to date to $5.5m.
BioInnovation Capital... |
| 19.11.2018 | QurAlis Raises $5.5 Million Seed Round | CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases, today announced the raising of a seed extension, bringing the total funding to d... |
| 19.11.2018 | ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ticket to LabCentral | Neurodegenerative disease startup QurAlis has extended the seed round it first announced this past April, bringing its total funding up to $5.5 million.
Based on the work of a pair of Harvard University professors and their labs, QurAlis' s... |
| 19.11.2018 | ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ticket to LabCentral | Neurodegenerative disease startup QurAlis has extended the seed round it first announced this past April, bringing its total funding up to $5.5 million.
Sponsored by Agilent Technologies
How would you like to win free bench space at Lab Cen... |
| 19.11.2018 | QurAlis Raises $5.5M Seed Round |
CAMBRIDGE, MA, QurAlis announced the raising of a seed extension, bringing the total funding to date to $5.5 million.
>> Click here for more funding data on QurAlis
>> To export QurAlis funding data to PDF and Excel, click h... |
| 12.09.2018 | Startup Spotlight: Pfizer taps two neuroscience startups for incubator prize | Just months after Pfizer slashed hundreds of jobs in its own neuroscience R&D program, the pharmaceutical giant is making notable investments in two Boston-based neuroscience startups.
The company announced Wednesday that Tevard Bioscie... |
| 05.04.2018 | Amgen backs Harvard professors’ ALS startup QurAlis | QurAlis has raised seed funding from a syndicate featuring Amgen Ventures. The startup will use the cash to advance treatments for three subtypes of amyotrophic lateral sclerosis (ALS).
Amgen joined with MP Healthcare Venture Management and... |
| 05.04.2018 | Amgen backs Harvard professors’ ALS startup QurAlis
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | QurAlis has raised seed funding from a syndicate featuring Amgen Ventures. The startup will use the cash to advance treatments for three subtypes of amyotrophic lateral sclerosis (ALS).
Sponsored by Agilent Technologies
How would you like t... |
| 05.04.2018 | QurAlis Raises Seed Funding | QurAlis Corporation, a Cambridge, MA-based new private biotech company focused on developing precision solutions to cure ALS, raised a seed funding round of undisclosed amount.
Backers included MP Healthcare Venture Management (MPH), Amgen ... |
| 04.04.2018 | Harvard big-shots Kevin Eggan and Clifford Woolf launch ALS startup with exclusive Q-State tech | A group of well-known Harvard professors has launched a new ALS spinout to take on research Big Pharma wasn’t tackling fast enough.
Clifford Woolf
The new company, called QurAlis (pronounced “cure-al-is”), was founded by a coup... |
| - | QurAlis | “QurAlis is a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.” |
| - | QurAlis raises $42M in Series A round to develop therapies for ALS | Healthcare startups that have raised funding rounds this week include a firm developing a way to diagnose Alzheimer’s disease with a blood sample, a firm that combines technology with modern clinics to create a seamless virtual care to clin... |
